X

Biotechnology

With a Phase 2 success, Entera Bio’s pipeline might be worth betting on

Reporting by Arjun Vijay While rising interest in biotechnology has provided a much-needed fillip to the research and development of…

Entera Bio Ltd. (ENTX) Q4 2020 Earnings Call Transcript

Entera Bio Ltd. (NASDAQ: ENTX) Q4 2020 earnings call dated Mar. 18, 2021 Corporate Participants: Jonathan Lieber -- Chief Financial…

Avid Bioservices, Inc. (CDMO) Q3 2021 Earnings Call Transcript

Avid Bioservices, Inc. (NASDAQ: CDMO) Q3 2021 earnings call dated Mar. 08, 2021 Corporate Participants: Tim Brons -- Investor Relations Nicholas Green -- President…

Moderna (MRNA) to increase vaccine supply capacity and accelerate pipeline investments

Shares of Moderna Inc. (NASDAQ: MRNA) were up 6% in morning trade on Thursday after the company reported its fourth…

Sage Therapeutics Inc. (SAGE) Q4 2020 Earnings Call Transcript

Sage Therapeutics Inc. (NASDAQ: SAGE) Q4 2020 earnings call dated Feb. 24, 2021 Corporate Participants: Jeff Boyle -- Vice President, Head of…

Jazz Pharmaceuticals PLC (JAZZ) Q4 2020 Earnings Call Transcript

Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) Q4 2020 earnings call dated Feb. 23, 2021 Corporate Participants: Andrea N. Flynn -- Vice President, Head…

Solid pipeline makes ImmunoGen (IMGN) a good long-term investment

ImmunoGen Inc. (NASDAQ: IMGN) last week reported a profit after incurring losses in the first three quarters of last year.…

ImmunoGen Inc. (IMGN) Q4 2020 Earnings Call Transcript

ImmunoGen Inc. (NASDAQ: IMGN) Q4 2020 earnings call dated Feb. 12, 2021 Corporate Participants: Courtney O'Konek -- Senior Director of Corporate Communications…

Corcept Therapeutics Incorporated (CORT) Q4 2020 Earnings Call Transcript

Corcept Therapeutics Incorporated (NASDAQ: CORT) Q4 2020 earnings call dated Feb. 08, 2021 Corporate Participants: Charles Robb -- Chief Financial Officer Joseph…

Eylea recovery, COVID antibody cocktail make Regeneron an attractive bet

After last year's mixed performance, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) looks to take advantage of the robust pipeline and the…

Regeneron Pharmaceuticals, Inc. (REGN) Q4 2020 Earnings Call Transcript

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Q4 2020 earnings call dated Feb. 05, 2021 Corporate Participants: Justin Holko — Vice President, Investor Relations…

Bristol Myers (BMY) stock gains after Q4 results beat Street view

Bristol-Myers Squibb Company (NYSE: BMY) Thursday reported stronger-than-expected fourth-quarter results. The company's stock gained in the pre-market session soon after…

Biogen, Inc. (BIIB) Q4 2020 Earnings Call Transcript

Biogen, Inc. (NASDAQ: BIIB) Q4 2020 earnings call dated Feb. 03, 2021 Corporate Participants: Mike Hencke -- Director, Investor Relations Michel Vounatsos -- Chief…

Infographic: Key financials of Biogen (BIIB) Q4 2020 earnings report

Biogen (NASDAQ: BIIB) reported fourth-quarter 2020 financial results before the opening bell on Wednesday. The biotechnology giant reported a 22%…

Vertex Pharmaceuticals Inc (VRTX) Q4 2020 Earnings Call Transcript

Vertex Pharmaceuticals Inc  (NASDAQ: VRTX) Q4 2020 earnings call dated Feb. 01, 2021 Corporate Participants: Michael Partridge -- Senior Vice President of…

Novavax (NVAX) brings its share to the COVID-19 vaccine table; stock soars

Novavax Inc.’s (NASDAQ: NVAX) shares soared 50% in morning hours on Friday after the company announced that its COVID-19 vaccine…

Fate Therapeutics (FATE) looks headed for a turnaround post-COVID

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharma company, has been drawing the market's attention after reporting positive results from…

Codexis (CDXS) may be moving closer to profitability, after beating slowdown

Biosciences company Codexis, Inc. (NASDAQ: CDXS) has emerged stronger from a rough patch, supported mainly by the resilience of its…

Covid vaccine won’t dent Ampio Pharma’s market: CEO Michael Macaluso

Since its foundation in 2008, Ampio Pharmaceuticals (NYSE: AMPE) has been focused on delivering a drug that treats inflammation caused…

Moderna (MRNA): Development programs, additional approvals provide optimism

Moderna Inc. (NASDAQ: MRNA) seems to be on a roll right now. The stock has skyrocketed over 500% in the…

Moderna’s (MRNA) stock gains on COVID-19 vaccine approval from the European Commission

Shares of Moderna Inc. (NASDAQ: MRNA) gained 6.3% in afternoon hours on Wednesday as the company received approval from the…